Heron Therapeuti
USUSDHeron Therapeuti (US:HRTX) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- herontx.com
- Взаимодействие с инвесторами
- ir.herontx.com/
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-квартира
- SAN DIEGO, United States
- Генеральный директор
- Craig Alexander Collard
- Сотрудники
- 128
- Акций в обращении
- 189.85 млн на 2026-08-05
- Свободное обращение
- 146.52 млн
- Рыночная капитализация
- 77.1 млн USD
- Инсайдеры
- 0.98%
- Институциональные инвесторы
- 70.98%
- Отрасль (SIC)
- Pharmaceutical Preparations
- Коэффициент выплат
- 0%
- FCF
- −12.1 млн USD
- Долг
- 64.0 тыс USDденег больше, чем долга
- Стаж дивидендов
- —
- Прибыль, FCF и выплаченные дивиденды — за 12 месяцев до 30.06.2026 (последний отчёт компании).
Описание
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 10.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| Rubric Capital Managemen… | 15.83% | 30.05 млн | 2026-06-30 |
| Clearline Capital, LP | 6% | 11.38 млн | 2026-06-30 |
| Blackrock Inc. | 5.56% | 10.55 млн | 2026-06-30 |
| MORGAN ADAM (Director) | ≈4.68% | 8.88 млн | 2026-01-30 |
| Velan Capital Investment… | 4.61% | 8.75 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.1% | 7.78 млн | 2026-06-30 |
| Tejara Capital Ltd | 3.43% | 6.51 млн | 2026-06-30 |
| Tang Capital Management,… | 3.29% | 6.25 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.88% | 5.47 млн | 2026-06-30 |
| Geode Capital Management… | 2.25% | 4.27 млн | 2026-06-30 |
| Millennium Management Ll… | 2.14% | 4.07 млн | 2026-06-30 |
| JW Asset Management, LLC | 1.98% | 3.75 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.91% | 3.63 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.09% | 2.06 млн | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.86% | 1.63 млн | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.72% | 1.37 млн | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.46% | 869 904 | 2026-05-31 |
| COLLARD CRAIG ALEXANDER… | ≈0.45% | 856 492 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.41% | 783 992 | 2026-05-31 |
| Fidelity Concord Street… | 0.33% | 635 712 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.28% | 533 800 | 2026-08-31 |
| iShares Trust-iShares Ru… | 0.27% | 504 982 | 2026-08-31 |
| DUARTE IRA (Chief Financ… | ≈0.15% | 281 899 | 2026-07-31 |
| FORBES WILLIAM P (Office… | ≈0.13% | 241 173 | 2026-07-31 |
| HENSLEY MARK EARL (Chief… | ≈0.09% | 170 901 | 2026-08-06 |
| RODRIGUEZ SUSAN (Directo… | ≈0.05% | 87 180 | 2025-01-31 |
| CUSACK THOMAS J (Directo… | ≈0.03% | 53 960 | 2026-01-30 |
| JOHNSON CRAIG A (Directo… | ≈0.03% | 53 960 | 2026-01-30 |
| KASETA MICHAEL (Director… | ≈0.03% | 53 960 | 2026-01-30 |
| RUBRIC CAPITAL MANAGEMEN… | — | — | 2025-10-15 |
